C4 Therapeutics (CCCC) Non-Current Deffered Revenue (2019 - 2026)

C4 Therapeutics' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 38.53% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $15.4 million (down 38.53% YoY), while the FY2025 annual figure was $15.8 million, down 44.33% from the prior year.
• Non-Current Deffered Revenue was $15.4 million for Q1 2026 at C4 Therapeutics, down from $15.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $28.6 million in Q3 2024 to a low of $15.4 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $20.3 million across 5 years, with a median of $19.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Non-Current Deffered Revenue sank 62.62% in 2022, then jumped 45.99% in 2024.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $16.9 million in 2022, then increased by 29.12% to $21.8 million in 2023, then soared by 30.45% to $28.5 million in 2024, then plunged by 44.33% to $15.8 million in 2025, then slipped by 2.53% to $15.4 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $15.4 million (Q1 2026), $15.8 million (Q4 2025), and $19.9 million (Q3 2025), per Business Quant data.